Valeant Pharmaceuticals International, Inc.
VRX
position
long
Bill Ackman
Thesis
Ackman discusses the challenges of GAAP accounting for companies like Valeant, suggesting that while it has been acquisitive, the focus should be on understanding the economic earnings rather than just reported earnings. This indicates a belief in the potential value of the company despite its accounting complexities.
Did it work?
inconclusive
confidence: low
Without specific price performance data or a defined time frame for the thesis, it's difficult to assess whether the investment thesis has played out. The focus on economic earnings versus GAAP accounting is a valid consideration, but without knowing how Valeant's stock has performed or any developments in its financial reporting, we cannot determine the outcome of the pitch.
Raw excerpt
No raw excerpt stored.